{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:34:58Z","timestamp":1786980898714,"version":"build-2736575974"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,11,5]],"date-time":"2015-11-05T00:00:00Z","timestamp":1446681600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s10620-015-3897-0","type":"journal-article","created":{"date-parts":[[2015,11,5]],"date-time":"2015-11-05T01:48:33Z","timestamp":1446688113000},"page":"358-370","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis"],"prefix":"10.1007","volume":"61","author":[{"given":"Gary R.","family":"Lichtenstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,5]]},"reference":[{"key":"3897_CR1","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(12)60150-0","volume":"380","author":"I Ord\u00e1s","year":"2012","unstructured":"Ord\u00e1s I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012;380:1606\u20131619.","journal-title":"Lancet"},{"key":"3897_CR2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","volume":"142","author":"NA Molodecky","year":"2012","unstructured":"Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46\u201354.","journal-title":"Gastroenterology"},{"key":"3897_CR3","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.giec.2014.03.005","volume":"24","author":"A Walsh","year":"2014","unstructured":"Walsh A, Palmer R, Travis S. Mucosal healing as a target of therapy for colonic inflammatory bowel disease and methods to score disease activity. Gastrointest Endosc Clin N Am. 2014;24:367\u2013378.","journal-title":"Gastrointest Endosc Clin N Am"},{"key":"3897_CR4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4291\/wjgp.v5.i2.54","volume":"5","author":"C Pagnini","year":"2014","unstructured":"Pagnini C, Menasci F, Festa S, Rizzatti G, Delle FG. \u201cMucosal healing\u201d in ulcerative colitis: between clinical evidence and market suggestion. World J Gastrointest Pathophysiol. 2014;5:54\u201362.","journal-title":"World J Gastrointest Pathophysiol"},{"key":"3897_CR5","first-page":"243","volume":"26","author":"M Kalafateli","year":"2013","unstructured":"Kalafateli M, Triantos C, Theocharis G, et al. Health-related quality of life in patients with inflammatory bowel disease: a single-center experience. Ann Gastroenterol. 2013;26:243\u2013248.","journal-title":"Ann Gastroenterol"},{"key":"3897_CR6","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1097\/01.mib.0000235831.01682.8d","volume":"12","author":"EV Loftus Jr","year":"2006","unstructured":"Loftus EV Jr. A practical perspective on ulcerative colitis: patients\u2019 needs from aminosalicylate therapies. Inflamm Bowel Dis. 2006;12:1107\u20131113.","journal-title":"Inflamm Bowel Dis"},{"key":"3897_CR7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3109\/00365521.2012.685750","volume":"48","author":"E Nurmi","year":"2013","unstructured":"Nurmi E, Haapam\u00e4ki J, Paavilainen E, Rantanen A, Hillil\u00e4 M, Arkkila P. The burden of inflammatory bowel disease on health care utilization and quality of life. Scand J Gastroenterol. 2013;48:51\u201357.","journal-title":"Scand J Gastroenterol"},{"key":"3897_CR8","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/ajg.2009.727","volume":"105","author":"A Kornbluth","year":"2010","unstructured":"Kornbluth A, Sachar DB, The Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501\u2013523.","journal-title":"Am J Gastroenterol"},{"key":"3897_CR9","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.crohns.2012.09.002","volume":"6","author":"A Dignass","year":"2012","unstructured":"Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6:991\u20131030.","journal-title":"J Crohns Colitis"},{"key":"3897_CR10","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/apt.12712","volume":"39","author":"S Danese","year":"2014","unstructured":"Danese S, Siegel CA, Peyrin-Biroulet L. Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther. 2014;39:1095\u20131103.","journal-title":"Aliment Pharmacol Ther"},{"key":"3897_CR11","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/j.1572-0241.2008.01836.x","volume":"103","author":"JD Lewis","year":"2008","unstructured":"Lewis JD, Gelfand JM, Troxel AB, et al. Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol. 2008;103:1428\u20131435.","journal-title":"Am J Gastroenterol"},{"key":"3897_CR12","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cgh.2006.03.002","volume":"4","author":"GR Lichtenstein","year":"2006","unstructured":"Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn\u2019s disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621\u2013630.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3897_CR13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0928-0987(97)00082-1","volume":"6","author":"N Esmailpour","year":"1998","unstructured":"Esmailpour N, H\u00f6gger P, Rohdewald P. Binding kinetics of budesonide to the human glucocorticoid receptor. Eur J Pharm Sci. 1998;6:219\u2013223.","journal-title":"Eur J Pharm Sci"},{"key":"3897_CR14","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1155\/1990\/708916","volume":"4","author":"R Brattsand","year":"1990","unstructured":"Brattsand R. Overview of newer glucocorticosteroid preparations for inflammatory bowel disease. Can J Gastroenterol. 1990;4:407\u2013414.","journal-title":"Can J Gastroenterol"},{"key":"3897_CR15","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1053\/j.gastro.2012.08.003","volume":"143","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, Travis S, Moro L, et al. Once-daily budesonide MMX\u00ae extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology. 2012;143:1218\u20131226.","journal-title":"Gastroenterology"},{"key":"3897_CR16","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/gutjnl-2012-304258","volume":"63","author":"SP Travis","year":"2014","unstructured":"Travis SP, Danese S, Kupcinskas L, et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut. 2014;63:433\u2013441.","journal-title":"Gut"},{"key":"3897_CR17","doi-asserted-by":"crossref","first-page":"S-564","DOI":"10.1016\/S0016-5085(12)62168-4","volume":"142","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, Danese S, Ballard ED, et al. Efficacy of budesonide MMx\u00ae 6\u00a0mg QD for the maintenance of remission in patients with ulcerative colitis: results from a phase III, 12\u00a0month safety and extended use study [Abstract Su2080]. Gastroenterology. 2012;142:S-564.","journal-title":"Gastroenterology"},{"key":"3897_CR18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1053\/gast.1996.v110.pm8536887","volume":"110","author":"GR Greenberg","year":"1996","unstructured":"Greenberg GR, Feagan BG, Martin F, The Canadian Inflammatory Bowel Disease Study Group, et al. Oral budesonide as maintenance treatment for Crohn\u2019s disease: a placebo-controlled, dose-ranging study. Gastroenterology. 1996;110:45\u201351.","journal-title":"Gastroenterology"},{"key":"3897_CR19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1365-2036.1998.00285.x","volume":"12","author":"A Ferguson","year":"1998","unstructured":"Ferguson A, Campieri M, Doe W, Persson T, Nygard G, The Global Budesonide Study Group. Oral budesonide as maintenance therapy in Crohn\u2019s disease\u2014results of a 12-month study. Aliment Pharmacol Ther. 1998;12:175\u2013183.","journal-title":"Aliment Pharmacol Ther"},{"key":"3897_CR20","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1136\/gut.42.4.493","volume":"42","author":"V Gross","year":"1998","unstructured":"Gross V, Andus T, Ecker KW, The Budesonide Study Group, et al. Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn\u2019s disease. Gut. 1998;42:493\u2013496.","journal-title":"Gut"},{"key":"3897_CR21","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/00042737-199903000-00011","volume":"11","author":"K Ewe","year":"1999","unstructured":"Ewe K, Bottger T, Buhr HJ, Ecker KW, Otto HF, The German Budesonide Study Group. Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn\u2019s disease: a multicentre randomized placebo-controlled trial. Eur J Gastroenterol Hepatol. 1999;11:277\u2013282.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3897_CR22","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0016-5085(99)70125-3","volume":"116","author":"G Hellers","year":"1999","unstructured":"Hellers G, Cortot A, Jewell D, The IOIBD Budesonide Study Group, et al. Oral budesonide for prevention of postsurgical recurrence in Crohn\u2019s disease. Gastroenterology. 1999;116:294\u2013300.","journal-title":"Gastroenterology"},{"key":"3897_CR23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2036.2005.02338.x","volume":"21","author":"S Hanauer","year":"2005","unstructured":"Hanauer S, Sandborn WJ, Persson A, Persson T. Budesonide as maintenance treatment in Crohn\u2019s disease: a placebo-controlled trial. Aliment Pharmacol Ther. 2005;21:363\u2013371.","journal-title":"Aliment Pharmacol Ther"},{"key":"3897_CR24","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1053\/cgh.2003.50015","volume":"1","author":"GJ Mantzaris","year":"2003","unstructured":"Mantzaris GJ, Petraki K, Sfakianakis M, et al. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2003;1:122\u2013128.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3897_CR25","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1542-3565(04)00662-7","volume":"3","author":"EJ Schoon","year":"2005","unstructured":"Schoon EJ, Bollani S, Mills PR, et al. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2005;3:113\u2013121.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3897_CR26","first-page":"339","volume":"65","author":"DJ Jong de","year":"2007","unstructured":"de Jong DJ, Bac DJ, Tan G, et al. Maintenance treatment with budesonide 6\u00a0mg versus 9\u00a0mg once daily in patients with Crohn\u2019s disease in remission. Neth J Med. 2007;65:339\u2013345.","journal-title":"Neth J Med"},{"key":"3897_CR27","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/gut.48.2.186","volume":"48","author":"A Cortot","year":"2001","unstructured":"Cortot A, Colombel JF, Rutgeerts P, et al. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn\u2019s disease. Gut. 2001;48:186\u2013190.","journal-title":"Gut"},{"key":"3897_CR28","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1365-2036.2008.03891.x","volume":"29","author":"GR Lichtenstein","year":"2009","unstructured":"Lichtenstein GR, Bengtsson B, Hapten-White L, Rutgeerts P. Oral budesonide for maintenance of remission of Crohn\u2019s disease: a pooled safety analysis. Aliment Pharmacol Ther. 2009;29:643\u2013653.","journal-title":"Aliment Pharmacol Ther"},{"key":"3897_CR29","first-page":"86","volume":"122","author":"\u00c5 Ryrfeldt","year":"1982","unstructured":"Ryrfeldt \u00c5, Andersson P, Edsb\u00e4cker S, T\u00f6nnesson M, Davies D, Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis Suppl. 1982;122:86\u201395.","journal-title":"Eur J Respir Dis Suppl"},{"key":"3897_CR30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0090-9556(25)06497-9","volume":"23","author":"G J\u00f6nsson","year":"1995","unstructured":"J\u00f6nsson G, \u00c5str\u00f6m A, Andersson P. Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab Dispos. 1995;23:137\u2013142.","journal-title":"Drug Metab Dispos"},{"key":"3897_CR31","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/01.MIB.0000158386.25660.1e","volume":"11","author":"C Prantera","year":"2005","unstructured":"Prantera C, Viscido A, Biancone L, Francavilla A, Giglio L, Campieri M. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis. 2005;11:421\u2013427.","journal-title":"Inflamm Bowel Dis"},{"key":"3897_CR32","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.2174\/092986710791111170","volume":"17","author":"G Fiorino","year":"2010","unstructured":"Fiorino G, Fries W, De La Rue SA, Malesci AC, Repici A, Danese S. New drug delivery systems in inflammatory bowel disease: MMX\u2122 and tailored delivery to the gut. Curr Med Chem. 2010;17:1851\u20131857.","journal-title":"Curr Med Chem"},{"key":"3897_CR33","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/j.1365-2036.2006.03082.x","volume":"24","author":"G D\u2019Haens","year":"2006","unstructured":"D\u2019Haens G, Hommes D, Engels L, et al. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. Aliment Pharmacol Ther. 2006;24:1087\u20131097.","journal-title":"Aliment Pharmacol Ther"},{"key":"3897_CR34","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cgh.2006.10.025","volume":"5","author":"GR Lichtenstein","year":"2007","unstructured":"Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007;5:95\u2013102.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3897_CR35","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1053\/j.gastro.2006.10.011","volume":"132","author":"MA Kamm","year":"2007","unstructured":"Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007;132:66\u201375.","journal-title":"Gastroenterology"},{"key":"3897_CR36","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/gut.2007.138248","volume":"57","author":"MA Kamm","year":"2008","unstructured":"Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut. 2008;57:893\u2013902.","journal-title":"Gut"},{"key":"3897_CR37","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/ajg.2012.103","volume":"107","author":"G D\u2019Haens","year":"2012","unstructured":"D\u2019Haens G, Sandborn WJ, Barrett K, Hodgson I, Streck P. Once-daily MMX\u00ae mesalamine for endoscopic maintenance of remission of ulcerative colitis. Am J Gastroenterol. 2012;107:1064\u20131077.","journal-title":"Am J Gastroenterol"},{"key":"3897_CR38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2125.2005.02517.x","volume":"61","author":"M Brunner","year":"2006","unstructured":"Brunner M, Ziegler S, Di Stefano AF, et al. Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation. Br J Clin Pharmacol. 2006;61:31\u201338.","journal-title":"Br J Clin Pharmacol"},{"key":"3897_CR39","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1046\/j.1365-2036.2003.01426.x","volume":"17","author":"S Edsb\u00e4cker","year":"2003","unstructured":"Edsb\u00e4cker S, Bengtsson B, Larsson P, et al. A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules. Aliment Pharmacol Ther. 2003;17:525\u2013536.","journal-title":"Aliment Pharmacol Ther"},{"key":"3897_CR40","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1046\/j.1365-2036.2001.00910.x","volume":"15","author":"P Lundin","year":"2001","unstructured":"Lundin P, Naber T, Nilsson M, Edsb\u00e4cker S. Effect of food on the pharmacokinetics of budesonide controlled ileal release capsules in patients with active Crohn\u2019s disease. Aliment Pharmacol Ther. 2001;15:45\u201351.","journal-title":"Aliment Pharmacol Ther"},{"key":"3897_CR41","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1358\/dot.2004.40.7.850477","volume":"40","author":"JJ Kolkman","year":"2004","unstructured":"Kolkman JJ, Mollmann HW, Mollmann AC, et al. Evaluation of oral budesonide in the treatment of active distal ulcerative colitis. Drugs Today (Barc). 2004;40:589\u2013601.","journal-title":"Drugs Today (Barc)"},{"key":"3897_CR42","volume-title":"Uceris (budesonide) extended release tablets, for oral use [package insert]","author":"Salix Pharmaceuticals, Inc","year":"2014","unstructured":"Salix Pharmaceuticals, Inc. Uceris (budesonide) extended release tablets, for oral use [package insert]. Raleigh, NC: Salix Pharmaceuticals, Inc. 2014."},{"key":"3897_CR43","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1177\/0300060513476588","volume":"41","author":"A Nicholls","year":"2013","unstructured":"Nicholls A, Harris-Collazo R, Huang M, Hardiman Y, Jones R, Moro L. Bioavailability profile of Uceris MMX extended-release tablets compared with Entocort EC capsules in healthy volunteers. J Int Med Res. 2013;41:386\u2013394.","journal-title":"J Int Med Res"},{"key":"3897_CR44","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/jhep.2003.50266","volume":"38","author":"W Hempfling","year":"2003","unstructured":"Hempfling W, Grunhage F, Dilger K, Reichel C, Beuers U, Sauerbruch T. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology. 2003;38:196\u2013202.","journal-title":"Hepatology"},{"key":"3897_CR45","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1478-3231.2005.01222.x","volume":"26","author":"K Dilger","year":"2006","unstructured":"Dilger K, Cascorbi I, Grunhage F, Hohenester S, Sauerbruch T, Beuers U. Multidrug resistance 1 genotype and disposition of budesonide in early primary biliary cirrhosis. Liver Int. 2006;26:285\u2013290.","journal-title":"Liver Int"},{"key":"3897_CR46","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1677\/joe.0.1780339","volume":"178","author":"RJ Farrell","year":"2003","unstructured":"Farrell RJ, Kelleher D. Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol. 2003;178:339\u2013346.","journal-title":"J Endocrinol"},{"key":"3897_CR47","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/apt.13076","volume":"41","author":"WJ Sandborn","year":"2015","unstructured":"Sandborn WJ, Danese S, D\u2019Haens G, et al. Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9\u00a0mg: pooled analysis of two phase 3 studies. Aliment Pharmacol Ther. 2015;41:409\u2013418.","journal-title":"Aliment Pharmacol Ther"},{"key":"3897_CR48","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1097\/00054725-201112002-00066","volume":"17","author":"S Travis","year":"2011","unstructured":"Travis S, Ballard ED. Induction of remission with oral budesonide MMXVR (9\u00a0mg) tablets in patients with mild to moderate, active ulcerative colitis: a multicenter, open-label efficacy and safety study [Abstract]. Inflamm Bowel Dis. 2011;17:S20.","journal-title":"Inflamm Bowel Dis"},{"key":"3897_CR49","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJM199409293311304","volume":"331","author":"P Rutgeerts","year":"1994","unstructured":"Rutgeerts P, L\u00f6fberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn\u2019s disease. N Engl J Med. 1994;331:842\u2013845.","journal-title":"N Engl J Med"},{"key":"3897_CR50","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1053\/j.gastro.2008.09.012","volume":"135","author":"MD Kappelman","year":"2008","unstructured":"Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn\u2019s disease and ulcerative colitis in United States children and adults. Gastroenterology. 2008;135:1907\u20131913.","journal-title":"Gastroenterology"},{"key":"3897_CR51","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1007\/s10620-012-2289-y","volume":"57","author":"C Gunnarsson","year":"2012","unstructured":"Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Lofland JH. Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey. Dig Dis Sci. 2012;57:3080\u20133091.","journal-title":"Dig Dis Sci"},{"key":"3897_CR52","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2165\/11584820-000000000-00000","volume":"29","author":"K Bodger","year":"2011","unstructured":"Bodger K. Cost effectiveness of treatments for inflammatory bowel disease. Pharmacoeconomics. 2011;29:387\u2013401.","journal-title":"Pharmacoeconomics"},{"key":"3897_CR53","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.3748\/wjg.v20.i15.4329","volume":"20","author":"LA Feagins","year":"2014","unstructured":"Feagins LA, Iqbal R, Spechler SJ. Case-control study of factors that trigger inflammatory bowel disease flares. World J Gastroenterol. 2014;20:4329\u20134334.","journal-title":"World J Gastroenterol"},{"key":"3897_CR54","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1111\/j.1572-0241.2001.04683.x","volume":"96","author":"SV Kane","year":"2001","unstructured":"Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001;96:2929\u20132933.","journal-title":"Am J Gastroenterol"},{"key":"3897_CR55","first-page":"s2","volume":"14","author":"SV Kane","year":"2008","unstructured":"Kane SV, Brixner D, Rubin DT, Sewitch MJ. The challenge of compliance and persistence: focus on ulcerative colitis. J Manag Care Pharm. 2008;14:s2\u2013s12.","journal-title":"J Manag Care Pharm"},{"key":"3897_CR56","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1365-2036.2006.02809.x","volume":"23","author":"SV Kane","year":"2006","unstructured":"Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006;23:577\u2013585.","journal-title":"Aliment Pharmacol Ther"},{"key":"3897_CR57","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/1471-230X-12-132","volume":"12","author":"D Mitra","year":"2012","unstructured":"Mitra D, Hodgkins P, Yen L, Davis KL, Cohen RD. Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis. BMC Gastroenterol. 2012;12:132.","journal-title":"BMC Gastroenterol"},{"key":"3897_CR58","volume-title":"Entocort EC (budesonide) capsules [package insert]","author":"AstraZeneca LP","year":"2012","unstructured":"AstraZeneca LP. Entocort EC (budesonide) capsules [package insert]. Wilmington, DE: AstraZeneca LP. 2012."},{"key":"3897_CR59","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S1542-3565(03)70032-9","volume":"1","author":"S Kane","year":"2003","unstructured":"Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol. 2003;1:170\u2013173.","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-015-3897-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-015-3897-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-015-3897-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T05:19:37Z","timestamp":1748668777000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-015-3897-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,5]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["3897"],"URL":"https:\/\/doi.org\/10.1007\/s10620-015-3897-0","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,5]]}}}